{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Number of unique patients who had treatment related (possible, probable or definite) adverse events that were graded 3 or greater.","groups":[{"description":"Original portion of the study where patients received Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D.","id":"OG000","title":"Original Study - Revlimid, Cyclophosphamide, Prednisone"},{"description":"Extension portion of the study where patients received Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D.","id":"OG001","title":"Extension - Revlimid, Cyclophosphamide, Prednisone"}],"paramType":"NUMBER","populationDescription":"All patients enrolled and received treatment.","reportingStatus":"POSTED","timeFrame":"Beginning of treatment up to 5 years","title":"Treatment Related Adverse Events Grade 3 or Higher","type":"SECONDARY","unitOfMeasure":"participants"}